Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 206-211, July 2001

The role of nuclear medicine in monitoring treatment in skeletal malignancy

  • Gary J.R. Cook

      Affiliations

    • Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, Surrey, England
    • Department of Nuclear Medicine, Guy's Hospital, London, England
    • Corresponding Author InformationAddress reprint requests to Gary J.R. Cook, MD, Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, England.
    • ,
  • Ignac Fogelman

      Affiliations

    • Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, Surrey, England
    • Department of Nuclear Medicine, Guy's Hospital, London, England

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0001-2998(01)80020-9

doi:10.1053/snuc.2001.23527

Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 206-211, July 2001

Article Tools